Laboratory studies demonstrate that ES2 peptides show 3-7 times more potent senolytic activity than FOXO4-DRI in both in vitro and in vivo experimental systems, while CPP-CAND demonstrates approximately 1.2-fold higher selectivity despite shorter peptide length
Semaglutide is usually started at a lower dose to help reduce side effects, and the effects may become more noticeable as the medication builds over time or as the dose increases
Additionally, consistent application, paired with sunscreen, prevents re-darkening, as advised by the NHS for maintaining skin health
I think we're looking at opportunities for enhancement
however, some detrimental effects have also been reported
Alopecia as an Emerging Adverse Effect of GLP-1 Receptor Agonists: A Scoping Review